Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
114

Summary

Conditions
  • Acute Myeloid Leukemia (AML)
  • Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
Type
Interventional
Phase
Phase 1Phase 2
Design
Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Younger than 621 years
Gender
Both males and females

Description

Not Provided

Not Provided

Tracking Information

NCT #
NCT04240002
Collaborators
Not Provided
Investigators
Study Director: Medical Director Astellas Pharma Global Development